PTGX Protagonist Therapeutics, Inc.
$141.12▲ +0.57%
Healthcare
Other
After hours
$141.12▲ +0.00%
Oct 27, 4:05 PM ET
Volume 865.9K
Avg Volume (10D) 736.1K
Key Metrics & Fundamentals
Market Cap
$9.13B
P/E Ratio
137.0
Div Yield
0.00%
52W Range
74.80 - 160.81
% vs 50 MA
-1.70%
% vs 200 MA
21.97%
RSI-14
52.1
MACD Histogram
+0.5500
Beta (1Y vs SPY)
0.86
Free Cash Flow
$218.88M
Gross Rev
$213.48M
Gross Profit
$213.48M
EBITDA
$159.16M
COGS
–
Operating Exp
$54.71M
Operating Income
$158.77M
EBIT
$158.77M
Pretax Income
$165.11M
Net Income
$162.85M
EPS (Diluted)
2.29
Price & Volume History
Loading chart…
Recent News
Protagonist Therapeutics to Participate in Four Investment Bank Conferences in November 2026
ACCESS Newswire · Oct 27, 2026 7:00 AM ET
J&J Stock Reclaims 50-Day SMA: Is it Time to Buy, Sell or Hold?
Zacks · Oct 23, 2026 8:37 AM ET
A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday
CNW Group · Oct 20, 2026 8:59 AM ET
Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should Know
Zacks · Oct 15, 2026 11:00 AM ET
UBS Initiates Coverage on Protagonist Therapeutics With Buy Rating, $184 Price Target
MT Newswires · Oct 12, 2026 7:38 AM ET
The Peptide Boom That Isn’t About Your Muscles
The Wall Street Journal · Sep 25, 2026 5:30 AM ET
Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight
GlobeNewswire · Sep 21, 2026 1:00 PM ET
J&J Up 18% in Three Months: Buy, Sell or Hold the Stock?
Zacks · Sep 18, 2026 9:05 AM ET
Protagonist Therapeutics Insider Sold Shares Worth $18,240,568, According to a Recent SEC Filing
MT Newswires · Sep 11, 2026 3:23 AM ET
Protagonist Therapeutics Announces $300 Million Share Repurchase Program
ACCESS Newswire · Sep 8, 2026 4:05 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See PTGX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.